Mallinckrodt Study Shows Acthar Primary Endpoint Not Met in Patients with Persistently Active Systemic Lupus Erythematosus

Loading...
Loading...
Data presented yesterday by researchers for Mallinckrodt plc
MNK
suggest that H.P. Acthar® Gel (repository corticotropin injection) reduces certain measures of disease activity in patients with persistently active Systemic Lupus Erythematosus (SLE) who are receiving corticosteroid therapy. The pilot study data were presented at a poster session during the 2015 American College of Rheumatology (ACR)/Association of Rheumatology Health Professionals (ARHP) Annual Meeting in San Francisco being held Nov. 7-11, 2015.  "Acthar demonstrated clinically relevant improvement in signs and symptoms of lupus in patients who need an alternative therapy for persistent symptoms," said Steven Romano, M.D., Senior Vice President and Chief Scientific Officer, Mallinckrodt Pharmaceuticals. "This is one of many studies Mallinckrodt is pursuing related to Acthar. We are encouraged by the results of this small study, and the potential Acthar may hold for patients with persistently active SLE." Acthar is approved by the U.S. Food and Drug Administration (FDA) for use during an exacerbation or as a maintenance therapy in select patients with SLE. For this pilot study, while certain secondary endpoints of the
See full press release
Posted In: NewsM&APress Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...